These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3391005

  • 1. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J, LLerena A, Cobaleda J.
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [Abstract] [Full Text] [Related]

  • 2. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO.
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [Abstract] [Full Text] [Related]

  • 3. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J, Lindberg R, Huupponen R, Iisalo E.
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [Abstract] [Full Text] [Related]

  • 4. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL.
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [Abstract] [Full Text] [Related]

  • 5. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [Abstract] [Full Text] [Related]

  • 6. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ, Villén T, Alm C, Bertilsson L.
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [Abstract] [Full Text] [Related]

  • 7. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.
    Agúndez JA, Martínez C, Ledesma MC, Ladona MG, Ladero JM, Benítez J.
    Clin Pharmacol Ther; 1994 Apr; 55(4):412-7. PubMed ID: 7909282
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
    Philip PA, James CA, Rogers HJ.
    Br J Clin Pharmacol; 1987 Dec; 24(6):827-9. PubMed ID: 3440103
    [Abstract] [Full Text] [Related]

  • 12. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S, Patamasucon P, Lee EJ.
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Debrisoquine oxidation in Parkinson's disease.
    Kallio J, Marttila RJ, Rinne UK, Sonninen V, Syvälahti E.
    Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.